170 related articles for article (PubMed ID: 23932065)
1. Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease.
van Dijk KD; Jongbloed W; Heijst JA; Teunissen CE; Groenewegen HJ; Berendse HW; van de Berg WD; Veerhuis R
Parkinsonism Relat Disord; 2013 Dec; 19(12):1079-83. PubMed ID: 23932065
[TBL] [Abstract][Full Text] [Related]
2. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.
Compta Y; Martí MJ; Ibarretxe-Bilbao N; Junqué C; Valldeoriola F; Muñoz E; Ezquerra M; Ríos J; Tolosa E
Mov Disord; 2009 Nov; 24(15):2203-10. PubMed ID: 19795497
[TBL] [Abstract][Full Text] [Related]
4. Quantification of clusterin in paired cerebrospinal fluid and plasma samples.
Jongbloed W; Herrebout MA; Blankenstein MA; Veerhuis R
Ann Clin Biochem; 2014 Sep; 51(Pt 5):557-67. PubMed ID: 24146185
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
6. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
7. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.
Compta Y; Ibarretxe-Bilbao N; Pereira JB; Junqué C; Bargalló N; Tolosa E; Valldeoriola F; Muñoz E; Camara A; Buongiorno M; Martí MJ
Parkinsonism Relat Disord; 2012 Sep; 18(8):941-7. PubMed ID: 22595621
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
9. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
Johansson A; Zetterberg H; Håkansson A; Nissbrandt H; Blennow K
Neurodegener Dis; 2005; 2(1):28-35. PubMed ID: 16909000
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
Holmberg B; Johnels B; Blennow K; Rosengren L
Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between cognitive impairment and plasma levels of clusterin/ApoJ in Parkinson disease patients not affected by dementia].
Niccoli Asabella A; Ruggeri M; Rubini D; Polimeno L; Spinelli C; Polito M; Pennelli M; Altini C; De Caro MS; Defazio G; Rubini G
Recenti Prog Med; 2013; 104(7-8):393-7. PubMed ID: 24042414
[TBL] [Abstract][Full Text] [Related]
12. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms.
Nilselid AM; Davidsson P; Nägga K; Andreasen N; Fredman P; Blennow K
Neurochem Int; 2006 Jun; 48(8):718-28. PubMed ID: 16490286
[TBL] [Abstract][Full Text] [Related]
13. Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity.
van Dijk KD; Bidinosti M; Weiss A; Raijmakers P; Berendse HW; van de Berg WD
Eur J Neurol; 2014 Mar; 21(3):388-94. PubMed ID: 23631635
[TBL] [Abstract][Full Text] [Related]
14. CSF markers of neurodegeneration in Parkinson's disease.
Přikrylová Vranová H; Mareš J; Nevrlý M; Stejskal D; Zapletalová J; Hluštík P; Kaňovský P
J Neural Transm (Vienna); 2010 Oct; 117(10):1177-81. PubMed ID: 20730548
[TBL] [Abstract][Full Text] [Related]
15. Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease.
van Dijk KD; Persichetti E; Chiasserini D; Eusebi P; Beccari T; Calabresi P; Berendse HW; Parnetti L; van de Berg WD
Mov Disord; 2013 Jun; 28(6):747-54. PubMed ID: 23712522
[TBL] [Abstract][Full Text] [Related]
16. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease.
Trupp M; Jonsson P; Ohrfelt A; Zetterberg H; Obudulu O; Malm L; Wuolikainen A; Linder J; Moritz T; Blennow K; Antti H; Forsgren L
J Parkinsons Dis; 2014; 4(3):549-60. PubMed ID: 24927756
[TBL] [Abstract][Full Text] [Related]
17. Clusterin CSF levels in differential diagnosis of neurodegenerative disorders.
Přikrylová Vranová H; Hényková E; Mareš J; Kaiserová M; Menšíková K; Vaštík M; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2016 Feb; 361():117-21. PubMed ID: 26810527
[TBL] [Abstract][Full Text] [Related]
18. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
20. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.
Mollenhauer B; Trenkwalder C; von Ahsen N; Bibl M; Steinacker P; Brechlin P; Schindehuette J; Poser S; Wiltfang J; Otto M
Dement Geriatr Cogn Disord; 2006; 22(3):200-8. PubMed ID: 16899997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
